PMID- 37648337
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230901
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 9
DP  - 2023 Sep
TI  - Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial 
      Carcinoma: Early Experience in the Real World.
PG  - 4055-4060
LID - 10.21873/anticanres.16594 [doi]
AB  - BACKGROUND/AIM: This study retrospectively investigated the impact of enfortumab 
      vedotin (EV) monotherapy on the oncological outcome, safety profile, and 
      health-related quality of life (HRQoL) in patients with metastatic urothelial 
      carcinoma. PATIENTS AND METHODS: We assessed 26 consecutive patients who had 
      received EV monotherapy after failure of platinum-based chemotherapy and immune 
      checkpoint blockade therapy at our single institution from December 2021 to 
      January 2023. The objective response rate (ORR), disease control rate (DCR), 
      progression-free survival (PFS), overall survival (OS), incidence of adverse 
      events (AEs), and EORTC QLQ-C30 as an HRQoL instrument were evaluated. RESULTS: 
      The ORR and DCR were 57.7% and 80.8%, respectively. EV was effective regardless 
      of the patient and tumor characteristics, including the efficacy of previous 
      systemic therapy, performance status, number of Bellmunt risk factors, and 
      presence of variant histology. With a median follow-up time of 7.5 months, the 
      median durations of PFS and OS were 5.4 months and 10.3 months, respectively. 
      Grade >/=3 AEs included neutropenia (15.4%), fatigue (7.7%), appetite loss (7.7%), 
      rash (3.8%), febrile neutropenia (3.8%), hyperglycemia (3.8%), and interstitial 
      pneumonia (3.8%). AEs resulting in withdrawal of EV, interruption of EV, and dose 
      reduction occurred in two (7.7%), nine (34.6%), and 13 patients (50.0%), 
      respectively. The EORTC QLQ-C30 scores from baseline to post-EV introduction 
      remained stable. CONCLUSION: EV monotherapy demonstrated promising anti-tumor 
      activity and tolerability in patients with metastatic urothelial carcinoma.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Minato, Akinori
AU  - Minato A
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan; a-minato@med.uoeh-u.ac.jp.
FAU - Kimuro, Rieko
AU  - Kimuro R
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Ohno, Daichi
AU  - Ohno D
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Tanigawa, Kentarou
AU  - Tanigawa K
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Kuretake, Keisuke
AU  - Kuretake K
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Matsukawa, Takuo
AU  - Matsukawa T
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Takaba, Tomohisa
AU  - Takaba T
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Jojima, Kazumasa
AU  - Jojima K
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Harada, Mirii
AU  - Harada M
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Higashijima, Katsuyoshi
AU  - Higashijima K
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Nagata, Yujiro
AU  - Nagata Y
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Tomisaki, Ikko
AU  - Tomisaki I
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Harada, Kenichi
AU  - Harada K
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Fujimoto, Naohiro
AU  - Fujimoto N
AD  - Department of Urology, School of Medicine, University of Occupational and 
      Environmental Health, Kitakyushu, Japan.
FAU - Miyamoto, Hiroshi
AU  - Miyamoto H
AD  - Department of Pathology & Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - DLE8519RWM (enfortumab vedotin)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Transitional Cell
MH  - Quality of Life
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms
MH  - *Neutropenia
OTO - NOTNLM
OT  - Enfortumab vedotin
OT  - antibody-drug conjugate
OT  - bladder cancer
OT  - upper urinary tract cancer
OT  - urothelial carcinoma
EDAT- 2023/08/31 00:41
MHDA- 2023/09/01 06:43
CRDT- 2023/08/30 20:54
PHST- 2023/05/31 00:00 [received]
PHST- 2023/06/28 00:00 [revised]
PHST- 2023/06/29 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/08/31 00:41 [pubmed]
PHST- 2023/08/30 20:54 [entrez]
AID - 43/9/4055 [pii]
AID - 10.21873/anticanres.16594 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Sep;43(9):4055-4060. doi: 10.21873/anticanres.16594.